Corporate News-Good Doctor

Blog

——

Corporate News

Industry News

Hyperthermic Perfusion Podcast

Notice & Announcement

2024.09.27

GDHIPEC: Science-Based Innovation, Patented Technology, Trusted Performance, Expanding Global Markets

They are pioneers in the field of tumor hyperthermia in our country and practitioners of dreams. Their mission is to improve the quality of life for cancer patients, embarking on the journey of developing intraperitoneal hyperthermia treatment machines. They are the Good Doctor team, a group of indomitable dream chasers. Through their actions, they interpret persistence and dedication, painting a hopeful picture for the field of tumor hyperthermia treatment in our country.

2026.09.10

Good Doctor·Hyperthermic Perfusion | Literature Brief Review | Current Clinical Applications and Future Prospects of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Advanced Ovarian Cancer

Ovarian cancer is the leading cause of cancer-related mortality among malignant tumors of the female reproductive system. The disease has an insidious onset, and approximately 75% of patients are already at an advanced stage at the time of initial diagnosis, often accompanied by extensive peritoneal dissemination throughout the pelvic and abdominal cavities.

2026.09.03

Good Doctor·Hyperthermic Intraperitoneal Chemotherapy | Interpretation of the 2026 Edition CACA Guidelines for HIPEC Clinical Application

Since the early 1980s, when American general surgeon John Spratt [Spratt JS, et al. Cancer Res. 1980; 40: 256–260] first reported the successful use of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat peritoneal pseudomyxoma (PMP), CRS plus HIPEC has become the preferred or effective treatment for a variety of primary or secondary (metastatic) peritoneal malignancies. Currently, across 51 countries and regions worldwide, at least 138 expert consensuses or guidelines have been published on the use of CRS plus HIPEC for treating various peritoneal malignancies [Tonello M, et al. Ann Surg Oncol. 2025; 32: 5795–5806].

2026.09.02

Good Doctor · Hyperthermic Perfusion | Literature Brief Review | Current Clinical Applications and Future Prospects of CRS + HIPEC in the Treatment of Pseudomyxoma Peritonei (PMP)

Pseudomyxoma Peritonei (PMP) is a rare malignant neoplasm of the peritoneal surface, characterized by copious mucinous ascites and widespread peritoneal implantation. Approximately 90% of cases originate from rupture of an appendiceal mucinous tumor, with a smaller proportion arising from the ovary, colon, or other sites. Its natural history exhibits “benign behavior with malignant distribution”: tumor cells demonstrate low proliferative activity, yet their continuous secretion of mucin leads to progressive abdominal distension, organ compression, and intestinal obstruction. Conventional repeated cytoreductive surgery yields a 5-year survival rate of less than 50%.

2026.08.21

Good Doctor·Hyperthermic Intraperitoneal Chemotherapy | Literature Review | Clinical Advances and Future Explorations of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastases from Colorectal Cancer

Colorectal cancer is one of the most common malignancies worldwide, posing a serious threat to human health. Each year, approximately 1.926 million new cases of colorectal cancer are diagnosed globally, and about 904,000 deaths are attributed to this disease.

2026.08.21

Good Doctor · Hyperthermic Perfusion | Literature Brief Review | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Metastasis: Current Status and Future Prospects

According to reports from 2020, there were 1.09 million new cases of gastric cancer worldwide, making it the fifth most common cancer; deaths from gastric cancer totaled 770,000, ranking it fourth. In China, more than 500,000 cancer patients have peritoneal metastases from gastric cancer.

2026.08.21

Good Doctor·Hyperthermic Perfusion | Literature Review and Analysis | (8) “A Comparative Study of the Efficacy of CCCHP and CHP in Treating Malignant Effusions”

Intracavitary hyperthermic perfusion chemotherapy devices can maintain an effective therapeutic temperature within the body cavity and ensure continuous circulation, with efficacy significantly superior to that of single‑dose, non‑circulatory intracavitary hyperthermic perfusion chemotherapy; there was no difference in the incidence of adverse events between the two groups.

2026.08.21

Good Doctor·Hyperthermic Perfusion | Literature Review and Analysis | (7) “Clinical Study on Cytoreductive Surgery Combined with Intraperitoneal Hyperthermic Perfusion Chemotherapy for Peritoneal Metastases of Gastric Cancer”

This study evaluated the therapeutic efficacy and adverse effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from gastric cancer, following cytoreductive surgery (CRS).

< 1 2 3 4 5 6 > proceed page

· GDHIPEC from China ,

· Caring for Patients Worldwide ·

Tel.: +86 29 82681864

Sales service hotline: +86 15002902555

E-mail: gd029@126.com

Address: Floor 1-2, Left Building No. 1, Huoju Road, East zone of Xi’an High- tech Development District, Xi’an, China

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Internet Drug Information Service Qualification Certificate (Shaanxi)-Non-Operating -2023-0143

Blog

COOKIES

COOKIES

Sorry，The current column has no content!